HealthcareLarge capRs 46,507 crRs 139.7 cr traded a dayMultinationalsPharmaceuticals
Close on 2026-08-21
2,819.30
−0.02%
52-week range89% of the way up
1,596.802,970.20
Market cap
46,507 cr
P/E (TTM)
41.2×
industry 44×
EPS (TTM)
68.43
Revenue YoY
+19.6%
Q1 FY27
Profit YoY
+47.1%
Net margin
17.6%
+3.3pt vs a year ago
Growth trend
-2.7pt
vs last quarter’s YoY
1 month
+18.6%
Below 52w high
5.4%
RSI (14)
67
Daily swing
3.6%
average true range
Volume
0.3×
vs 20-day average
Traded
Rs 140 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−5.08%
1 month
+18.57%
3 months
+22.16%
6 months
+51.48%
1 year
+51.01%
The read
written from the numbers on this page
The evidence leans constructive7 supporting, 0 against, 0 worth knowing
Supporting
trading 42% above its 200-day average
sitting at 89% of its 52-week range, with little overhead supply from trapped buyers
up 51% over twelve months
matches the market's strongest stocks, which has beaten the market by +0.37 points over 20 sessions across 48,607 past signals
3 independent kinds of evidence agree today, which is uncommon
revenue grew 20% year on year in the quarter ending 2026-06-30
net margin has widened from 12.4% to 17.6% across four quarters
Against
nothing the data supports either way
Worth knowing
nothing the data supports either way
GLAND sits in Multinationals, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 1,991, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net profit +47.1% year on year, Rs 215 cr to Rs 317 cr.
+47.1%Rs 215 crRs 317 cr
Profit rose year on year in all 4 of the last 4 quarters.
4
Profit grew faster than revenue, +47.1% against +19.6%.
+47.1%+19.6%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
8 of 47 matched on 2026-08-21
GLAND matches 8 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
GLAND trades at 41× trailing earnings, above its median of 38× over this window — 9% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · Management filings were typically -0.01pt vs the market over the next 5 sessions (n=1,988) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 20% against the same quarter a year earlier
profit rose 47% year on year
revenue rose in 3 of the last 4 quarters
Going against it
net margin narrowed from 21.0% to 17.6%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
1,800
435
317
19.23
17.6%
Q4 FY26
2026-03-31 · consolidated
1,743
506
367
22.26
21.0%
Q3 FY26
2025-12-31 · consolidated
1,695
362
261
15.87
15.4%
Q2 FY26
2025-09-30 · consolidated
1,487
284
184
11.15
12.4%
Q1 FY26
2025-06-30 · consolidated
1,506
313
215
13.08
14.3%
Q4 FY25
2025-03-31 · consolidated
1,425
288
187
11.32
13.1%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+12.2%
Versus 200-day average+41.6%
Below 52-week high-5.1%
Above 52-week low+76.6%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)67.2
Higher closes in last 50 of 5
Six-month return+51.48%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.58%
Volume versus 20-day0.3x
Median daily turnoverRs 139.7 cr
Peers
Healthcare · 67 classified companies
GLAND trades at 41.2× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — priced roughly in line with them. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.